OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, has announced the amalgamation of its wholly owned Singaporean subsidiaries, Stelis Pte. Limited and Onesource Specialty Pte. Limited. The amalgamation, effective from January 01, 2026, aims to simplify the corporate hierarchy, enhance operational efficiency, and reduce administrative, compliance, and legal costs.

For the financial year ended March 31, 2025, Stelis Pte. Limited reported a turnover of USD 7.86 million (approximately ₹65.3 crore), and Onesource Specialty Pte. Limited reported a turnover of USD 34.09 million (approximately ₹283 crore). Stelis Pte. is engaged in the manufacturing of pharmaceutical products, while Onesource Specialty Pte. focuses on developing, marketing, and distributing pharmaceutical goods, including injectables.

The transaction involves the cancellation of Stelis Pte. shares held by the parent company and the issuance of Onesource Specialty Pte. shares to OneSource Specialty Pharma Limited. As this is a transaction between wholly owned subsidiaries, it is not considered a related party transaction and will not impact the consolidated financial statements or the company's shareholding pattern.